8 in 8 Series: Neoadjuvant Biomarker Trials in Lung Cancer

Clinical Trials and Lung Cancer BiomarkersПодробнее

S1 Episode 4: Managing Lung Cancer With Neoadjuvant and Adjuvant TherapyПодробнее

STS Webinar: Biomarker Testing and Neoadjuvant Immunotherapy for Resectable NSCLCПодробнее

8 in 8 Series: Biomarker Testing and Neoadjuvant Immunotherapy for Resectable NSCLCПодробнее

Checkmate 816: Neoadjuvant Nivolumab + Chemotherapy for NSCLC - OncTalk Lung 2023Подробнее

8 in 8: Update on Immunotherapy for Resectable Lung CancerПодробнее

Optimizing neoadjuvant therapy in NSCLC with biomarker researchПодробнее

NAUTIKA1: targeted therapies in biomarker-selected stage IB-II NSCLCПодробнее

ASCO 2021 Lung Recap: Surgical Outcomes & Checkmate 816: Nivolumab in Early Stage NSCLCПодробнее

ASCO Lung Cancer Highlights, Part 8: The Biomarkers France StudyПодробнее

Dr. Gainor on Neoadjuvant Use of Biomarkers in Nonmetastatic Lung CancerПодробнее

Biomarkers, Immunotherapies, Combinations, and Other Emerging Approaches for Lung CancerПодробнее

Upcoming NSCLC trials in 2022: CheckMate 816 & KEYNOTE-091Подробнее

CheckMate 816 trial: Nivolumab + platinum-doublet chemotherapy vs chemo as neoadjuvant treatment...Подробнее

Biomarker identification in NSCLC treated with neoadjuvant chemo-IOПодробнее

Surgical endpoints are needed in lung cancer trials of neoadjuvant therapyПодробнее

Neoadjuvant biomarker analysis of NeoRHEA: palbociclib in ER+/HER2- BCПодробнее